The Asia Pacific single-cell analysis market is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a CAGR of 20.1% during the forecast period. Market growth is driven by factors such as growth in stem cell research, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, rising prevalence of cancer, and growing focus on personalized medicine. On the other hand, the high cost of single-cell analysis products is expected to limit market growth to a certain extent in the coming years.
The consumbles segment accounted for the highest growth rate in the Asia Pacific single-cell analysis market, by product, during the forecast period The Asia Pacific single-cell analysis market is segmented into consumables and instruments based on product.The consumables segment accounted for the highest growth rate in the Asia Pacific single-cell analysis market in 2019.
The frequent purchase of consumables as compared to instruments is the main factor contributing to this segment’s high growth rate.
Next-generation sequencing segment accounted for the highest CAGR Based on technique, the APAC single-cell analysis market is segmented into flow cytometry, next-generation sequencing, polymerase chain reaction, microscopy, mass spectrometry, and other techniques.In 2019, the next-generation sequencing segment accounted for the highest growth rate.
The advancements in NGS techniques and their wide application in drug discovery for cancer are the major factors driving this segment’s growth.
Academic & research laboratories segment accounted for the highest CAGR Based on end user, the APAC single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers.In 2019, the academic & research laboratories segment accounted for the highest growth rate.
This can be attributed to the increasing number of collaborations among research institutes and life science research companies and growing funding for life science research.
Japan: The fastest-growing country in the Asia Pacific single-cell analysis market The Asia Pacific single-cell analysis market is segmented into Japan, China, India, South Korea, Singapore, Australia, Southeast Asia, and the Rest of Asia Pacific.Japan is projected to register the highest CAGR during the forecast period.
Factors such as the increasing life science research activities, increasing demand for advanced treatment techniques, and growing focus on personalized medicine are driving the growth of the single-cell analysis market in Japan.
The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30% • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
Lists of Companies Profiled in the Report: • Becton, Dickinson and Company (US) • Danaher Corporation (US) • Merck Millipore (US) • QIAGEN N.V. (Netherlands) • Thermo Fisher Scientific, Inc. (US) • General Electric Company (US) • Promega Corporation (US) • Illumina, Inc. (US) • Bio-Rad Laboratories (US) • Fluidigm Corporation (US) • Agilent Technologies, Inc. (US) • Tecan Group Ltd. (Switzerland) • Sartorius AG (Germany) • Luminex Corporation (US) • Takara Bio (Japan) • 10x Genomics (US) • Fluxion Biosciences (US) • Menarini Silicon Biosystems, Inc. (Italy) • bioMérieux SA (France) • Oxford Nanopore Technologies (UK) • Cytek Biosciences (US) • Corning Incorporated (US) • Apogee Flow Systems Ltd. (UK) • NanoCellect Biomedical (US) • On-chip Biotechnologies Co., Ltd. (Japan)
Research Coverage: This report provides a detailed picture of the Asia Pacific single-cell analysis market.It aims at estimating the size and future growth potential of the market across different segments, such as product, cell type, technique, application, end user, and country.
The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Asia Pacific single-cell analysis market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
Our reports have been used by over 10K customers, including:
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% during the forecast period. Market growth is driven by factors The growing investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side-effects...
The anti-money laundering solution market was valued at US$ 1,503.99 million in 2019 and is projected to reach US$ 5,866.51 million by 2027; it is expected to grow at a CAGR of 16.2% from 2020 to 2027. Transaction monitoring is a crucial procedure and key control in anti-money laundering (AML) and countering the financing of terrorism (AML/CFT)...
The global recombinant proteins market is projected to reach USD 1.7billion by 2026 from USD 1.0billion in 2021, at a CAGR of 9.8% during the forecast period. The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industryacademia collaborations,...
206 pages •
By The Business Research Company
• Dec 2020
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market. Description: Where is the largest and fastest growing...
The market for cell culture is driven by factors such as rising demand for vaccines, artificial organs and biopharmaceuticals, and growing focus on personalized medicine. Immunization is the most valuable and cost-effective intervention that delivers better health as well as social and economic benefits. Annually, around 2 to 3 million...
The whole slide imaging market was valued at US$ 419.52 million in 2019 and is projected to reach US$ 1,582.12 million by 2027; it is expected to grow at a CAGR of 18.1% during 2020–2027. Technological advancements in whole slide imaging and increase in adoption of digital pathology. However, the high cost involved in the installation and...
The fill finish manufacturing market was valued at US$ 6,129.03 million in 2019 and is projected to reach US$ 12,547.23 million by 2027; it is expected to grow at a CAGR of 9.6% from 2020 to 2027. The growth of the fill finish manufacturing market is mainly attributed to factors such as rising adoption of prefilled syringes for parenteral...
317 pages •
By The Business Research Company
• Oct 2020
Oral Biologics & Biosimilars Global Market Opportunities And Strategies To 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics and biosimilars market.
Where is the largest and fastest growing market for the oral...
The injectable drugs market is expected to register a CAGR of nearly 11.1% during the forecast period. With an upsurge in the number of chronic diseases like diabetes and cancer, the need for drug delivery systems has risen substantially in the market. From the past one era of healthcare, biologics are increasingly becoming the driving...
Advancement in filling machine technology and growth in the manufacturing of lyophilized drugs are projected to drive the dual chamber syringe (DCS) filling machine market. The global installed base of dual chamber syringe (DCS) filling machine market size is projected to grow from USD 258 million in 2020 to USD 381 million by 2025, at...
Infectious Disease Mortality
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.